title: Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection.
abstract: Abnormal levels of inflammation are associated with cardiovascular disease and mortality in human immunodeficiency virus (HIV)-infected patients. Microbial translocation, which may cause inflammation, is decreased by sevelamer in patients undergoing hemodialysis. In this single-arm study, we evaluated the effects of 8 weeks of sevelamer therapy on 36 HIV-infected subjects who were not receiving antiretroviral therapy. Sevelamer did not significantly change markers of microbial translocation, inflammation, or T-cell activation. During sevelamer treatment, however, levels of soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol decreased significantly, whereas D-dimer levels increased. Thus, in this study population, sevelamer did not reduce microbial translocation but may have yielded cardiovascular benefits.
  
  
  BACKGROUND
  NCT 01543958.
authors.forename: Netanya G
authors.initials: NG
authors.lastname: Sandler
authors.forename: Xinyan
authors.initials: X
authors.lastname: Zhang
authors.forename: Ronald J
authors.initials: RJ
authors.lastname: Bosch
authors.forename: Nicholas T
authors.initials: NT
authors.lastname: Funderburg
authors.forename: Andrew I
authors.initials: AI
authors.lastname: Choi
authors.forename: Janet K
authors.initials: JK
authors.lastname: Robinson
authors.forename: Derek M
authors.initials: DM
authors.lastname: Fine
authors.forename: Robert W
authors.initials: RW
authors.lastname: Coombs
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Jacobson
authors.forename: Alan L
authors.initials: AL
authors.lastname: Landay
authors.forename: Daniel C
authors.initials: DC
authors.lastname: Douek
authors.forename: Randall
authors.initials: R
authors.lastname: Tressler
authors.forename: Sarah W
authors.initials: SW
authors.lastname: Read
authors.forename: Cara C
authors.initials: CC
authors.lastname: Wilson
authors.forename: Steven G
authors.initials: SG
authors.lastname: Deeks
authors.forename: Michael M
authors.initials: MM
authors.lastname: Lederman
authors.forename: Rajesh T
authors.initials: RT
authors.lastname: Gandhi
mesh_terms: D000328:Adult; D018988:Bacterial Translocation; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control; D008078:Cholesterol, LDL / Q000097:blood*; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D018950:Lipopolysaccharide Receptors / Q000097:blood; D008070:Lipopolysaccharides / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011073:Polyamines / Q000627:therapeutic use*; D000069603:Sevelamer; D013925:Thromboplastin / Q000032:analysis*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D002317:Cardiovascular Agents; D008078:Cholesterol, LDL; D018950:Lipopolysaccharide Receptors; D008070:Lipopolysaccharides; D008077:Lipoproteins, LDL; D011073:Polyamines; C099252:oxidized low density lipoprotein; D013925:Thromboplastin; D000069603:Sevelamer
keywords: HIV; LDL; LPS; microbial translocation; oxLDL; sCD14; sevelamer; soluble tissue factor